StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine,
"Regeneration-inducing Medicine".
| December 12, 2024 | Financial Results | [Delayed]Non-consolidated Financial Results for Three Months Ended October 31, 2024 [Japanese GAAP] |
|---|---|---|
| September 13, 2024 | Financial Results Presentation Materials | Presentation Materials Financial Results for the the Fiscal Year Ended July 31, 2024 |
| September 11, 2024 | Financial Results | Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2024 [Japanese GAAP] |
| July 01, 2024 | IR News | Noteice of Extraordinary General Meeting of Shareholders |
| June 12, 2024 | Financial Results | Non-consolidated Financial Results for the Nine Months Ended April 30, 2024 [Japanese GAAP] |
| April 25, 2023 | NEWS Release |
|---|
StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine, "Regeneration-inducing Medicine".
"Regeneration-inducing Medicine" is an innovative new class of medicine that induces functional regeneration of tissues and organs in the patient's body by maximizing the human body's innate ability of tissue repairing.
We are pursuing research and development of new drugs based on a novel mechanism of action leading to recruitment of the patients’ own in-vivo stem cells to the damaged tissues for functional tissue regeneration without conventional cell-therapy approaches.
